Nutriband (NTRB) said Friday that it received a patent in Macao for its abuse and misuse deterrent transdermal systems, which covers the company's Aversa abuse deterrent transdermal technology.
The company said the Macao Intellectual Property Office granted the patent on Feb. 11, adding to patents in 46 other countries for its abuse deterrent transdermal technology.
Nutriband said it is working with Kindeva Drug Delivery to develop Aversa Fentanyl, which integrates the Aversa abuse deterrent transdermal technology into Kindeva's transdermal fentanyl patch system.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.